Studies of Bruton's tyrosine kinase inhibitors in B-cell malignancies

by Walter, Harriet Sarah
Published 2018

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

by Philipp von Hundelshausen, Wolfgang Siess
Published 2021-03-01

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

by Zemene Demelash Kifle
Published 2021-09-01

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

by Hussein A. Abbas, William G. Wierda
Published 2021-05-01

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

by Irina V. Poddubnaya, Tatyana E. Bialik, Natalya N. Glonina, Olga B. Kalashnikova, Kamil D. Kaplanov, Valery A. Lapin, Nadezhda V. Medvedeva, Natalya B. Mikhailova, Tatyana N. Moiseeva, Evgeniy A. Nikitin, Tatyana I. Pospelova, Elena A. Stadnik
Published 2020-05-01

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

by Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta
Published 2021-02-01

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

by Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Niharika B Mettu, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu
Published 2020-06-01

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model

by Irfana Muqbil, Mahmoud Chaker, Amro Aboukameel, Ramzi M. Mohammad, Asfar S. Azmi, Radhakrishanan Ramchandren
Published 2019-08-01

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context

by Nicholas Van Rooij, MD, Jesse Johnston, MBBS, FACD, Rohan Mortimore, MBBS, FRCPA, Ivan Robertson, MBBS, FACD
Published 2021-07-01

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis...

by Kathleen M Gillooly, Claudine Pulicicchio, Mark A Pattoli, Lihong Cheng, Stacey Skala, Elizabeth M Heimrich, Kim W McIntyre, Tracy L Taylor, Daniel W Kukral, Shailesh Dudhgaonkar, Jignesh Nagar, Dana Banas, Scott H Watterson, Joseph A Tino, Aberra Fura, James R Burke
Published 2017-01-01

A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation

by Ali S. Abdelhameed, Mohamed W. Attwa, Nasser S. Al-Shaklia, Adnan A. Kadi
Published 2019-06-01

Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell...

by Eris Bame, Hao Tang, Jeremy C Burns, Million Arefayene, Klaus Michelsen, Bin Ma, Isaac Marx, Robin Prince, Allie M Roach, Urjana Poreci, Douglas Donaldson, Patrick Cullen, Fergal Casey, Jing Zhu, Thomas M Carlile, Dipen Sangurdekar, Baohong Zhang, Patrick Trapa, Joseph Santoro, Param Muragan, Alex Pellerin, Stephen Rubino, Davide Gianni, Bekim Bajrami, Xiaomei Peng, Alex Coppell, Katherine Riester, Shibeshih Belachew, Devangi Mehta, Mike Palte, Brian T Hopkins, Matthew Scaramozza, Nathalie Franchimont, Michael Mingueneau
Published 2021-01-01

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

by Ayad M. Al‐Katib, Hussein Gaith, Dahlia Sano, Sayf Al‐Katib, Michelle Bonnett, Zyad Kafri
Published 2020-09-01

Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence

by Andrei A. Petrenko, Maria I. Kislova, Elena A. Dmitrieva, Eugene A. Nikitin
Published 2021-08-01

A Review on Newer Tyrosine Kinase Inhibitors and their Uses

by NITHU M KUMAR, MEENU MATHEW, KN ANILA, S PRIYANKA
Published 2018-08-01

Targeted Treatment of Follicular Lymphoma

by Karthik Nath, Maher K. Gandhi
Published 2021-02-01

Multiple sclerosis in 2020

by Anshu Rohatgi, Neha Pandita
Published 2021-01-01

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

by Sara Bravaccini, Giovanni Martinelli, Claudio Cerchione
Published 2020-09-01

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

by Maria Tariq Siddiqui, Allyson Price, Alessandra Ferrajoli, Gautam Borthakur
Published 2021-01-01